Michael Chrisofos

National and Kapodistrian University of Athens

Papers

1

Total Citations

15

H-Index

1

About

Dr. Michael Chrisofos is a leading urologic oncologist whose research centers on the comparative effectiveness of minimally invasive treatments for renal cell carcinoma. His major contribution lies in rigorously evaluating the long-term oncologic outcomes of percutaneous microwave ablation versus robot-assisted partial nephrectomy for stage I kidney cancer. In a landmark 2024 propensity-matched cohort study, Dr. Chrisofos provided critical evidence that microwave ablation offers comparable cancer control to robotic surgery, with the added benefits of reduced invasiveness and faster recovery. This work, which has already garnered 15 citations, is shaping clinical decision-making for patients and surgeons alike. Beyond this key study, Dr. Chrisofos has advanced the field through his expertise in urologic imaging and thermal ablation techniques, helping to establish ablation as a viable first-line option for small renal masses. His research is notable for its focus on long-term follow-up, addressing a crucial gap in the literature. For students and researchers, Dr. Chrisofos’s work exemplifies how comparative effectiveness research can translate into practical, patient-centered improvements in cancer care.

Research Focus

Key Achievements

1
H-Index
1
Papers
15
Total Citations
15
Avg Citations/Paper
🏆 Most Cited Paper
Percutaneous Microwave Ablation Versus Robot-Assisted Partial Nephrectomy for Stage I Renal Cell Carcinoma: A Propensity-Matched Cohort Study Focusing Upon Long-Term Follow-Up of Oncologic Outcomes
15 citations · 2024
📈 Most Prolific Year: 2024 (1 Papers)
🤝 Key Collaborators: 6
🏛 Institutions: National and Kapodistrian University of Athens

Top Papers

  1. 1

Key Collaborators

Contact & Links

Available for collaboration
Content generated · 12 days ago